ArticleNAR genomics and bioinformatics2025
Joint analysis of
Article in NAR genomics and bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Rare exonic variant studies have previously implicated overlapping risk genes and pathways for autism spectrum disorder (ASD), severe, undiagnosed developmental disorders (UDDs), intellectual disability (ID), congenital heart disease (CHD), and schizophrenia (SCZ). Here, we use a two-trait Bayesian integrative analysis approach on 43 287 ASD, UDD/ID, CHD, and SCZ case trios to increase statistical power for gene discovery and to identify shared risk genes. At a posterior probability > 0.80, we identified 180 candidate risk genes for ASD, 315 for UDD/ID, 49 for CHD, and 47 for SCZ, including genes not previously reported, and also detected shared risk genes in pair-wise analyses. Gene set enrichment analysis of the ASD-UDD/ID, ASD-SCZ, and UDD/ID-SCZ shared risk genes overwhelmingly implicated gene sets associated with the synapse and epigenetic modification, while CHD-ASD shared risk genes were enriched in cell cycle phase transition gene sets, and CHD-UDD/ID shared risk genes implicated cardiac development. ASD-UDD/ID risk genes had elevated expression in interneurons and pyramidal cells, while ASD-UDD/ID and CHD-UDD/ID shared risk genes showed elevated connectivity in protein-protein interaction networks. Leveraging information across disorders with genetic overlap, both to increase power for candidate risk gene discovery and also as a method to elucidate shared genetic mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.